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Abstract: Hodgkins’ lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an 
  ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success 
of mAb therapy in the treatment on Non Hodgkins Lymphoma. The identification of CD30 as a potential target for treatment has led to 
the development of a new antibody-drug conjugate, brentuximab vedotin (SGN-35), which conjugates monomethyl auristatin E to an 
anti-CD30 antibody to deliver targeted toxicity to the malignant Reed Sternberg cells of HL. This review describes CD30 as an antibody 
target, and focuses on the antibody-drug conjugate brentuximab vedotin, including current knowledge of the mechanism of action, 
  preclinical, clinical and pharmacokinetic data available for Brentuximab Vedotin.
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Introduction
Hodgkins  Lymphoma  (HL)  accounts  for  approxi-
mately  30%  of  all  lymphoma.1  It  is  a  highly  cur-
able condition with a 5 year survival above 85%,2 
which is even higher in those patients with limited 
stage disease.3
Effective  combination  chemotherapy  for  HL 
began  with  the  MOPP  regimen  (Mechlorethamine, 
Vincristine,  Procarbazine  and  Prednisolone)4  pio-
neered by the National Cancer Institute, Bethesda. 
This has been superceded by ABVD (Adriamycin, 
Bleomycin,  Vinblastine  and  DTIC)5,6  which  was 
introduced in 19757 and is now widely regarded as 
the standard of care for first line treatment of HD in 
the United Kingdom and North America.8 Recently 
published data shows ABVD and the newer escalated 
BEACOPP  regimen,  widely  used  in  Europe,  both 
achieve 85%–50% 10 year overall survival, although 
less toxicity is seen with ABVD.9–12 The focus has 
now  moved  from  further  improving  efficacy  to 
reducing  the  late  toxicity  associated  with  some  of 
these therapies.
Despite  good  initial  responses  to  treatment, 
approximately 20%–30% of patients will relapse and 
require salvage therapy.13 In younger fitter patients 
second line treatment of those with either refractory 
or relapsed disease involves high dose therapy and 
autologous  stem  cell  transplant  (ASCT)  following 
salvage chemotherapy. Whilst ASCT may be curative, 
it will be ineffective in up to 50% of patients.14
For  older  or  less  fit  patients  ASCT  is  not  a 
therapeutic  option.  For  these  patients  or  younger 
patients relapsing after a stem cell transplant there 
is a need for newer effective therapies. Within this 
context  a  range  of  drugs  (including  gemcitabine, 
vinorelbine and cisplatin) have shown activity, either 
as single agent or in combination.15–18 Despite this 
there have been few studies directly comparing the 
many   different regimens to help inform the choice 
of therapy.
Identification of a Target for 
Monoclonal Antibody Therapy
The addition of antibody therapy to standard chemo-
therapy has resulted in a paradigm shift in the treatment 
of  Non-Hodgkins  Lymphoma  (NHL).19,20  In  this 
  context the CD20 antigen has proven a very effective 
target and as a consequence antigens associated with 
HL  have  been  sought.  However,  uniquely  among 
  cancers, the malignant cells of HL (Reed Sternberg 
(RS) cells) comprise only 1% of the tumour cells and 
are scattered throughout it.   Surrounding the RS cells 
(and driven by cytokine secretion from them)21,22 is a 
complex B and T cell rich environment which   supports 
tumour growth and provides an inflammatory milieu 
in which the RS cells can evade immune attack.23 
  Targeting the RS cells themselves would therefore 
seem  a  plausible  method  of  reducing  the  overall 
tumour burden.
One potential therapeutic option would be to target 
the B cell tumour microenvironment with the use of the 
anti CD20 antibody Rituximab, however it has recently 
emerged that maintaining the B cell environment may 
be beneficial. Gene expression profiling has shown a 
correlation between an improvement in progression-
free survival and disease-specific survival when there 
is a higher number of CD20+ B cells in the tumour.24
In this context the addition of rituximab to first 
line  combination  chemotherapy  is  currently  under 
investigation in an ongoing clinical trial.25
In  order  to  target  the  RS   cells  themselves 
monoclonal  antibodies  to  various  cell  surface 
immunotargets  have  been  investigated.  The  most 
attractive of these has been anti-CD30.
CD30 as a Target
CD30  was  discovered  in  198226  and  subsequently 
identified as a member of the TNF (tumour necrosis 
factor) superfamily.27 It is expressed on all RS cells 
and functions as an integral membrane glycoprotein. 
CD30  is  expressed  in  98.4%  HL  cases,28  and 
also  in  some  other  haematological  malignancies, 
most  notably  Anaplastic  Large  Cell  Lymphoma. 
Expression  of  CD30  is  also  highly  restricted  in 
normal tissue—it is only found in thymocytes during 
thymic development, decidual cells of the pregnant 
uterus  and  endometrium,  pancreatic  exocrine  cells 
and a subset of activated lymphocytes (both B and T 
(CD4+  and  CD8+)  cells29—making  it  a  good 
immunotherapy target that is unlikely to have many 
‘off target’ side effects.
CD30  signaling  appears  to  result  in  pleiotropic 
effects  depending  on  the  microenvironment  within 
which the cell resides.30,31 These effects are mediated 
by  interaction  of  the  long  cytoplasmic  domain  of 
CD30 with members of the TNFR associated factor Brentuximab vedotin (SGN-35) in Hodgkins Lymphoma
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(TRAF) family, which consequently activate NF κB,32 
responsible for anti-apoptotic gene induction. NF κB 
activation  can  however  be  pro-apoptotic  in  some 
cases, which may in part explain why the various 
anti-CD30 antibodies cause differing amounts of cell 
death in cell lines.33
As  well  as  potentially  stimulating  direct  cell 
death  via  CD30  activation,  the  use  of  therapeutic 
antibodies can potentially harness other mechanisms 
of cell death induction such as complement dependent 
cytotoxicity (CDC) and antibody dependent cellular   
cytotoxicity (ADCC).
Anti-cD30 Antibody Development
Despite encouraging in-vitro results, the first anti-
CD30 antibodies developed did not show significant 
therapeutic  effects  in  vivo.  SGN-30  (also  called 
cAC10)  is  a  chimeric  antibody,  consisting  of  the 
variable regions from a murine anti CD30 antibody 
(ac10) and the human regions of the gamma 1 heavy 
chain and lambda light chain. It was well tolerated 
in a phase 1 multidose study34 with no maximum 
tolerated  dose  identified.  The  more  significant 
adverse events (grade III/IV) all occurred at doses 
above  8  mg/kg  and  milder  adverse  events  were 
not  dose  related.  Unfortunately  in  a  subsequent 
phase  II  study,  no  patient  with  HL  achieved  an 
objective response, although 29% HL patients had 
stable disease.35
When  combined  with  the  chemotherapy  drugs 
Gemcitabine, Vinorelbine and liposomal Doxorubicin 
(GVD) in a randomized double blind phase II trial 
there were excess pulmonary adverse events in the 
GVD-SGN30  arm,  including  fatal  pneumonitis, 
necessitating closure of the trial.36
MDX060 is a fully human anti CD30 antibody 
which  also  demonstrates  minimal  effect  in  vivo, 
despite  promising  in  vitro  data.  Fewer  than  10% 
of  patients  in  the  phase  I  and  II  trials  responded 
objectively,37 although there was an indication that 
higher doses may increase PFS.38 Data regarding its 
effect in combination with chemotherapy have not 
been reported.
The  second  generation  anti-CD30  antibodies 
(MDX-1401  and  XmAb2513)  have  modified  Fc 
regions to increase efficacy39 but despite being well 
tolerated failed to reduce tumour burden significantly 
in phase I studies.40,41
In an attempt to increase the clinical activity of the 
anti-CD30 antibodies they were conjugated to tox-
ins (Antibody Drug Conjugates; ADC’s), using the 
‘naked’ (unconjugated) antibody as a vehicle for toxin 
delivery to tumour cells. This has the advantage of 
potentially sparing the normal tissue from the effects 
of  the  cytotoxic  agents. Although  it  is  possible  to 
conjugate radionuclides, RNAses and toxins to the 
antibodies, it is only the antibody/toxin combination 
that has been shown to have significant therapeutic 
effect without significant toxicity or the development 
of human anti-chimeric antibodies.
Brentuximab Vedotin (sGn-35)
The ADC Brentuximab Vedotin is under development 
by Seattle Genetics Inc and its licensee Millennium: 
the  Takeda  Oncology  Company.  It  consists  of  the 
anti-CD30  antibody  cAC10  (SGN  30)  conjugated 
to  monomethyl  auristatin  E  (MMAE).  This  is  a 
synthetic analogue of dolastatin 10, a natural product 
isolated  from  Dolabella  Auriculara  (Indian  Ocean 
sea hare) which acts as a potent anti-tubulin agent. 
The MMAE attaches to the antibody via a protease 
cleavable  dipeptide  bond. A  valine-citrulline  bond 
has been previously shown to exhibit superior linker 
stability  over  other  linker  technologies  (eg,  acid 
labile hydrazone linkers) with concurrently reduced 
toxicities during in vivo studies.42 Once the antibody 
has bound to CD30 it is internalized and trafficked to 
lysosomes, where the dipeptide bond is cleaved by 
cathepsin, a lysosomal protease, releasing the MMAE 
into the cell. The free MMAE then binds to tubulin 
within the cell disrupting the microtubule network 
leading to G2/M cell cycle arrest and apoptosis.43
preclinical studies
Initial production of SGN-35 conjugated 8 MMAE 
moieties  to  each  mAB42,43  however  subsequent 
studies  on  cell  lines  and  mouse  CD30+  xenograft 
models showed that reducing the number of MMAE 
structures  from  8  to  4  per  monoclonal  antibody 
molecule doubled the therapeutic index of the drug 
whilst  maintaining  efficacy  in  vivo.44 Accordingly, 
SGN-35 has an average of 4 drug moieties per antibody 
molecule and no free MMAE in the formulation.
Initial  studies  showed  that  the  addition  of 
the  conjugated  toxin  does  not  impact  on  the 
ability  of  the  antibody  to  bind  to  CD30  in  cell Table 1. Key preclinical trials for SGN-35 (to date).
study Year Key points
Francisco et al38 2003 Stable conjugation of MMAE to cAC10 
Exposure to ADC induces apoptosis in CD30+ cells (in vitro)
Oflazoglu et al47 2008 SGN-35 effective with combination chemotherapy (in vitro)
Fromm et al40 2010 Demonstrated SGN-35 internalisation kinetics
Okeley et al41 2010 MMAE released within CD30+ cells.  
Demonstrated bystander cell cytotoxicity
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lines—in vitro cytotoxicity studies showed high (up to 
4 log) selectivity for CD30-positive cells after 96 hours 
exposure. The stability of the dipeptide linker was also 
confirmed, with less than 2% of the MMAE being 
released when the ADC was incubated with human 
serum over a 10 day period. When HL cell lines were 
exposed to the ADC, apoptosis and DNA fragmentation 
began within 12 hours of exposure to the drug.43
Brentuximab  Vedotin  performed  well  in  further 
in-vitro  studies,  causing  growth  arrest  and  apop-
totic cell death in CD30+ cell lines (HL and ALCL). 
It has been shown that Brentuximab Vedotin internal-
izes within 48 hours of binding to cell surface CD30 
(faster in vivo than in vitro),45 and that the release of 
the MMAE from the antibody occurs within 24 hours 
of the internalization allowing a much higher MMAE 
concentration within the cells than the ADC concen-
tration administered.46
Interestingly  the  MMAE  released  into  the  cells 
after cleavage of the dipeptide linker seems to be able 
to diffuse out of viable HL cells and exert it’s cyto-
toxic effect on bystander cells.46 This may be very 
important in regression of a tumour such as HL where 
the malignant cells targeted constitute such a small 
percentage of the total tumour volume.
In  animal  models  significant  tumour  regression 
was  seen  in  mouse  xenograft  models  of  both  HL   




The results of the first multicentre phase I open label 
trial of Brentuximab Vedotin in relapsed/refractory 
HL have been published.47 This study comprised 45 
patients of which 42 had HL. They were heavily pre-
treated with an average of 3 previous lines of therapy 
(including  ASCT  in  all  eligible  and  consenting 
patients).  Although  there  was  no  upper  age  limit 
for  trial  eligibility,  the  majority  of  the  patients 
were young with a median age of 36, reflecting the 
demographics of this disease. Brentuximab Vedotin 
was  administered  once  every  3  weeks  at  doses 
escalating from 0.2 mg/kg to 3.6 mg/kg in a standard 
dose-escalation  trial  design,  followed  by  a  cohort 
expansion phase to evaluate safety aspects further. 
Figure 1. Mechanism of action.Brentuximab vedotin (SGN-35) in Hodgkins Lymphoma
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1.8 mg/kg was found to be the maximum tolerated 
dose  (MTD)  and  the  dose  limiting  toxicities  were 
febrile neutropenia, prostatitis and hyperglycaemia.
Of the total cohort an objective clinical response 
was seen in 35% patients (65% of these were complete 
remissions). Focusing on the HL patients in particular, 
an objective clinical response was seen in 21% (9/42) 
of the patients who had received #1.8 mg/kg, with 
a further 14 patients (33%) having stable disease. Of 
28 patients who received doses of $1.2 mg/kg and 
were evaluable 46% obtained an objective response 
(25%  complete  response  rate).  When  the  MTD  of 
1.8 mg/kg dose is examined alone, 50% (6/12) of the HL 
patients attained an objective clinical response (with a 
further 5 patients having stable disease). Importantly 
the responding patients included those with bulky or 
widespread disease and 4 of these 6 patients achieved 
complete remission, rare for a single agent treatment 
in heavily pretreated relapsed/refractory HL patients.
For all patients (including 3 NHL patients) respond-
ing to the drug at any dose, the Kaplan Meier estimate 
for objective response duration was 17.3 months with 
a median progression free survival of 5.9 months.
There  were  27  serious  adverse  events  reported 
during the trial, of which 14 occurred at a dose of 
1.8 mg/kg or lower. Of these 14 only 3 (hypercalcaemia, 
  myocardial  ischaemia  and    anaphylaxis)  were  felt 
to  be  related  to  the  Brentuximab    Vedotin.  The 
most   common adverse events were grade 1 and 2 
constitutional  symptoms  (fatigue,  pyrexia,  nausea) 
as  well  as    diarrhoea,  neutropenia  and  peripheral 
neuropathy. Most of the significant (grade 3 or 4) 
laboratory abnormalities, including neutropenia and 
thrombocytopenia, occurred at the higher drug doses 
(1.8 mg/kg or above).
In  total  a  significant  number  of  patients  (12; 
27%) withdrew from the trial due to adverse events, 
including 2 each for fatigue and thrombocytopenia.
In total 36% patients treated with the higher doses 
of drug (including the 1.8 mg/kg dose) experienced 
peripheral neuropathy, consistent with treatment with 
an  anti-tubulin  agent.  This  was  mostly  low  grade 
(I or II) and usually improved after drug cessation. 
The only grade 3 peripheral neuropathy occurred at a 
dose higher than the identified MTD.
A lower rate of human anti-chimeric   antibodies 
(HACA)  development  than  was  seen  with  the 
unconjugated SGN-30 was reported in this trial, with 
only 2 of the 40 patients tested developing HACA. 
Both of these patients had a best clinical response of 
stable disease. As the incidence of HACA   development 
in this trial is so low, no real conclusions can be drawn 
from this, however it will be of interest to monitor in 
future trials with this drug.
The addition of the toxin to the SGN 30 antibody 
can reasonably be assumed to account for the large 
difference in efficacy of the ADC compared to the 
SGN-30 antibody alone, and this study was the first 
to prove that the antibody could be efficiently used to 
deliver toxin to tumour cells selectively in vivo.
A further phase I study evaluated a more frequent 
(weekly)  infusion  regimen.
48  Brentuximab  Vedotin 
was administered weekly at doses of 0.4–1.4 mg/kg 
for 3 out of 4 weeks in each cycle. 33 out of the 
enrolled 44 patients had relapsed or refractory HL 
(median  of  3  prior  lines  of  therapy  and  62%  had 
received a previous ASCT). 52% patients achieved 
an  objective  response  (27%  complete  remissions). 
Compared with the 3 weekly dosing schedule, there 
was a marked increase in neuropathy with 10% of 
the patients   experiencing grade 3 neuropathy at the 
higher doses. As a consequence the 3 weekly regimen 
has been adopted for further studies.
phase II
In a large phase II single arm multicenter study49,50 
102 heavily pretreated patients were treated using the 
MTD dose of 1.8 mg/kg administered every 3 weeks. 
All  had  relapsed  following ASCT  and  the  median 
number  of  previous  therapies  was  4  (1–13).  The 
majority (70%) of the patients had primary refractory 
disease. The median number of cycles of Brentuximab 
Vedotin received was 9 (1–16).
Adverse  events  reported  in  this  trial  were 
predominantly grades 1 and 2 with the commonest 
being peripheral sensory neuropathy (43%), fatigue 
(40%),  nausea  (35%),  neutropenia  (19%),  diarrhea 
(18%) and pyrexia (16%). The more severe toxicities 
included  grade  3  neutropenia  (14%),  peripheral 
sensory neuropathy (5%), fatigue and hyperglycemia 
(3%  each)  and  grade  4  haematological  toxicities 
(neutropenia  (4%)  and  thrombocytopenia  (1%)), 
pulmonary embolism and abdominal pain (1% each).
The  overall  response  rate  was  75%  with  34% 
complete remission and 40% partial remission, and 
a median duration of response of 29 weeks (95% CI Table 2. Key clinical trials for SGN-35 (to date).
study phase Dosing Histology Total no of patients no of HL patients HL patients only
            ORR cR pR
Younes et al42 1 3 weekly HL, ALCL 45 42 15 (36%) 7 8
Fanale et al43 1 weekly HL, ALCL 44 33 17 (52%) 9 8
Chen et al45 2 (pivotal) 3 weekly HL 102 102 76 (75%) 35
Abbreviations: HL, Hodgkins Lymphoma; ALCL, Anaplastic Large Cell Lymphoma; Orr, Overall response rate; Cr, Complete remission; pr, partial 
remission.
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16–52).  For  patients  with  B  symptoms  at  the  start 
of treatment, 83% experienced a resolution of these 
symptoms by a median time of 3 weeks (range 1–16).
Based  on  this  trial  an  accelerated  approval 
  application was submitted to the FDA and approved in 
August 2011. Table 2 highlights the key clinical trials. 
potential for Retreatment
A case series presented at ASCO in 201051 describes 
patients  relapsing  following  treatment  with 
Brentuximab Vedotin and being re-treated with the 
drug. 7 patients had 8 re-treatments (6 of the 7 patients 
had  HL)  and  all  experienced  tumour    regression. 
Objectively there were 2 CR, 4 PR and 2 SD, showing 
that this ADC has the potential for repeated efficacy. 
A phase II re-treatment study is currently recruiting 
(NCT00947856, ClinicalTrials.gov).
pharmacokinetics
By performing various ELISA’s with anti idiotype 
antibodies  and  anti-MMAE  monoclonal  antibodies 
(for both capture and detection), it was found that the 
ADC is very stable in mice with a dipeptide linker 
half-life of 144 hours. When repeated in cynomolgus 
monkeys,  this  half-life  increased  to  230  hours, 
  raising hopes that it would be as stable in humans as 
in non-human primates.52 The increased duration of 
stability of the dipeptide linker helps reduce the dis-
parity between long monoclonal antibody half-lifes 
and  short  ‘linker’  half-lifes  that  complicates  many 
ADC’s, avoiding the problem of unconjugated mono-
clonal antibody binding to all potential targets and 
competing  with  conjugated  antibody  administered 
subsequently.
During the multicentre phase I trial, pharmacoki-
netic  and  pharmacodynamic  data  were  collected.47 
This demonstrated that the amount of free MMAE is 
proportional to the dose of the ADC.   Predictably, the 
highest concentration of ADC was found immediately 
after drug infusion, however it took 2–3 days   (estimated 
by  non-compartmental  methods)  for  the  MMAE 
concentration to peak. The half- life of the ADC is 
4–6 days (3–4 days for MMAE), consistent with the 
finding that steady state pharmacokinetics occurs after 
∼21 days. For the MTD of 1.8 mg/kg, concentration-
time data gave a mean area-under-the-curve of 76.65 
ug/mL for the ADC and 0.036 ug/mL for the MMAE, 
with a maximum mean   concentration of 31.98 ug/mL 
for the ADC and 0.05 ug/mL for the MMAE. This was 
achieved at a median time of 0.089 days for the ADC 
and 2.09 days for the MMAE.
As  TARC  (thymus  and  activation  related 
chemokine) levels have been previously correlated 
with HL activity53 serum TARC levels were evalu-
ated in the expansion phase of the phase 1 trial (12 
patients). Levels of TARC reduced in all these patients, 
however with such a small number of patients evalu-
ated it is difficult to extrapolate these results further. 
Although levels of various cytokines were analysed in 
the expansion phase of the trial, apart from decreases 
in interleukin-6 and TNF-α in 10 of the 12 patients no 
other results are reported.
combination with chemotherapy
Using mouse xenograft models of HL Brentuximab 
Vedotin  has  been  combined  with  chemotherapy. 
With  ABVD  and  Gemcitabine,  the  effects  appear 
synergistic. However with Vinorelbine no additional 
effect  was  evident.54  This  study  provided  a  good 
rationale for taking the combination of Brentuximab 
Vedotin  with  certain  chemotherapeutic  agents  into 
the clinical trial setting in the future, however given 
the high response rates achievable with first line ther-
apy, this may be more suitable to either the relapsed/ 
refractory  HL  population  or  more  elderly  patients 
who are unable to tolerate standard chemotherapy.Brentuximab vedotin (SGN-35) in Hodgkins Lymphoma
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Current Trials
The  combination  of  Brentuximab  Vedotin  therapy 
with ABVD as frontline treatment is currently under 
investigation  in  a  phase  I  study  (NCT01060904, 
  ClinicalTrials.gov). This aims to treat 70 patients and 
is now recruiting.
A  current  phase  III  trial  using  Brentuximab 
  Vedotin in HL is currently recruiting. This is a mul-
ticenter  double-blind  placebo-controlled  study: 
AETHERA  (NCT01100502;  SGN35-005,  Clinical-
Trials.gov)  comparing  Brentuximab  Vedotin  plus 
best supportive care versus placebo plus best support-
ive care for patients at high risk of residual HL after 
ASCT. The primary outcome measure is progression 
free survival with a secondary endpoint of overall   
survival.
A phase II/III trial (NCT01196208, ClinicalTrials.
gov) evaluating safety with Brentuximab Vedotin in 
HL is also available (expanded access).
At the time of writing, outside the US,   Brentuximab 
Vedotin is available to patients on a named patient   
basis.
Use in Other Diseases
As an anti-CD30 ADC, Brentuximab Vedotin has been 
trialed in systemic Anaplastic Large Cell   Lymphoma 
(ALCL) alongside the trials of HL, with most of the 
phase I trials being open to patients with either condi-
tion.47,48 ALCL is rare, accounting for 1%–2% of all 
NHL, and until now has been difficult to treat effec-
tively. Recent phase II multicenter study results of 
Brentuximab Vedotin as treatment for relapsed/refrac-
tory systemic ALCL55 has shown extremely promis-
ing results with 87% overall response rate and 57% 
CR rate. This is a significant advance and appears to 
be a breakthrough in the treatment of this condition.
It is possible that in the future, other hard to treat 
CD30+ diseases (eg, nasopharyngeal carcinoma) may 
benefit from the addition of this drug to existing treat-
ments. A study is currently recruiting patients with 
ALCL,  mycosis  fungoides  and  extensive    lymphomatoid 
papulosis for treatment with this drug (NCT01352520,   
ClinicalTrials.gov).
conclusion
Brentuximab Vedotin (SGN-35) is one of the most 
active ADC’s ever reported and has the potential to 
represent a significant advance in the treatment of 
Hodgkins  disease  and ALCL. At  a  time  when  the 
vast  majority  of  patients  will  respond  to  the  stan-
dard  first  line  combination  chemotherapy,  ABVD, 
it is likely that Brentuximab Vedotin will be a treat-
ment  of  choice  for  patients  with  few  other  effec-
tive  options  either  pre  or  post  ASCT,  providing 
significant  benefit  with  minimal  and  manageable   
toxicities.
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